Lysosomal acid lipase deficiency—a cautious leap forward

Lysosomal acid lipase deficiency can lead to liver failure and early death. A recently published placebo-controlled trial shows that enzyme-replacement therapy improves plasma levels of lipids and aminotransferases, and reduces liver fat content. However, the effect on clinical end points and an appropriate indication for treatment remain to be established.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Winchester, B. in Lysosomal Storage Disorders: A Practical Guide Ch. 5 (eds Mehta, A. & Winchester, B.) 37–48 (Wiley-Blackwell, 2012).

    Google Scholar 

  2. 2

    [No authors listed] Gaucher disease. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease. JAMA 275, 548–553 (1996).

  3. 3

    Weinreb, N. J. et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin. Hematol. 41 (4 Suppl. 5), 15–22 (2004).

    Article  Google Scholar 

  4. 4

    Cox, T. M. Innovative treatments for lysosomal diseases. Best Pract. Res. Clin. Endocrinol. Metab. 29, 275–311 (2015).

    CAS  Article  Google Scholar 

  5. 5

    Burton, B. K. et al. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N. Engl. J. Med. 373, 1010–1020 (2015).

    CAS  Article  Google Scholar 

  6. 6

    Bernstein, D. L., Hülkova, H., Bialer, M. G. & Desnick, R. J. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J. Hepatol. 58, 1230–1243 (2013).

    CAS  Article  Google Scholar 

  7. 7

    Hulková, H. & Elleder, M. Distinctive histopathological features that support a diagnosis of cholesterol ester storage disease in liver biopsy specimens. Histopathology 60, 1107–1113 (2012).

    Article  Google Scholar 

  8. 8

    Hollak, C. E., Aerts, J. M., Aymé, S. & Manuel, J. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J. Rare Dis. 6, 16 (2011).

    Article  Google Scholar 

  9. 9

    Stitziel, N. O. et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 33, 2909–2914 (2013).

    CAS  Article  Google Scholar 

  10. 10

    Rader, D. J. Lysosomal acid lipase deficiency—a new therapy for a genetic lipid disease. N. Engl. J. Med. 373, 1071–1073 (2015).

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Carla E. M. Hollak.

Ethics declarations

Competing interests

C.E.M.H. declares that the Academic Medical Center (AMC), Amsterdam, Netherlands, has received educational and research grants from Genzyme and Shire, and that she is an advisor for the Dutch Medicines Evaluation Board (CBG–MEB). G.K.H. declares that the Academic Medical Center (AMC), Amsterdam, Netherlands, has received grant support for clinical trials and consulting fees and/or honoraria from Amgen, Pfizer, Sanofi and Synageva.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hollak, C., Hovingh, G. Lysosomal acid lipase deficiency—a cautious leap forward. Nat Rev Endocrinol 11, 696–697 (2015). https://doi.org/10.1038/nrendo.2015.182

Download citation

Further reading


Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing